These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38419941)

  • 21. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals.
    Hung G; Xiao X; Peralta R; Bhattacharjee G; Murray S; Norris D; Guo S; Monia BP
    Nucleic Acid Ther; 2013 Dec; 23(6):369-78. PubMed ID: 24161045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
    Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
    Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung.
    Uemura Y; Hagiwara K; Kobayashi K
    PLoS One; 2017; 12(11):e0187286. PubMed ID: 29107995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro.
    Iwashita S; Shoji T; Koizumi M
    Methods Mol Biol; 2020; 2176():155-161. PubMed ID: 32865789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of 2'-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] modification on activity of gapmer antisense oligonucleotides containing 2',4'-constrained 2'-O-ethyl nucleic acid.
    Pandey SK; Nowak A; Perkins J; Ferng A; Prakash TP
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1688-1691. PubMed ID: 25804718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2'-
    Zhang L; Liang XH; De Hoyos CL; Migawa M; Nichols JG; Freestone G; Tian J; Seth PP; Crooke ST
    Nucleic Acid Ther; 2022 Oct; 32(5):401-411. PubMed ID: 35861704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region.
    Han K; Ito H; Elston R; Cremer J; Hood S; Paff M; Theodore D
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0090022. PubMed ID: 36507675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides.
    Wada F; Yamamoto T; Ueda T; Sawamura M; Wada S; Harada-Shiba M; Obika S
    Nucleic Acid Ther; 2018 Feb; 28(1):50-57. PubMed ID: 29360004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors Influencing ADME Properties of Therapeutic Antisense Oligonucleotides: Physicochemical Characteristics and Beyond.
    Jiang R; Hooshfar S; Rebecca Eno M; Yun C; Sonego Zimmermann E; Shinkyo R
    Curr Drug Metab; 2023; 24(7):536-552. PubMed ID: 37076460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Tolerability of GalNAc
    Baker BF; Xia S; Partridge W; Engelhardt JA; Tsimikas S; Crooke ST; Bhanot S; Geary RS
    Nucleic Acid Ther; 2024 Feb; 34(1):18-25. PubMed ID: 38227794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
    Kim TW; Kim KS; Seo JW; Park SY; Henry SP
    J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides.
    Wada F; Yamamoto T; Kobayashi T; Tachibana K; Ito KR; Hamasaki M; Kayaba Y; Terada C; Yamayoshi A; Obika S; Harada-Shiba M
    Mol Ther Nucleic Acids; 2021 Dec; 26():957-969. PubMed ID: 34760338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides.
    Yoshida T; Morihiro K; Naito Y; Mikami A; Kasahara Y; Inoue T; Obika S
    Nucleic Acids Res; 2022 Jul; 50(13):7224-7234. PubMed ID: 35801870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-pharmacodynamic modeling for hepatic delivery and efficacy of antisense oligonucleotides with lipophilic ligands in mice.
    Watanabe A; Katsube T
    Biopharm Drug Dispos; 2021 Apr; 42(4):178-187. PubMed ID: 33724506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
    Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, Tissue Distribution, and Metabolism of LNA-Containing Antisense Oligonucleotides in Rats.
    Romero-Palomo F; Festag M; Lenz B; Schadt S; Brink A; Kipar A; Steinhuber B; Husser C; Koller E; Sewing S; Tessier Y; Dzygiel P; Fischer G; Winter M; Hetzel U; Mihatsch MJ; Braendli-Baiocco A
    Toxicol Pathol; 2021 Aug; 49(6):1174-1192. PubMed ID: 34060347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
    J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins.
    Shen W; De Hoyos CL; Sun H; Vickers TA; Liang XH; Crooke ST
    Nucleic Acids Res; 2018 Mar; 46(5):2204-2217. PubMed ID: 29390093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides.
    Uemura Y; Kobayashi K
    Drug Deliv; 2019 Dec; 26(1):803-811. PubMed ID: 31385541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.